Cited by 212COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Researchinterferon and immune responses

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Open access

Hoang, Timothy N., Pino, Maria, Boddapati, Arun K., Viox, Elise G., Starke, Carly E., Upadhyay, Amit A., Gumber, Sanjeev, Nekorchuk, Michael, Busman-Sahay, Kathleen, Strongin, Zachary, Harper, Justin L., Tharp, Gregory K., Pellegrini, Kathryn L., Kirejczyk, Shannon, Zandi, Keivan, Tao, Sijia, Horton, Tristan R., Beagle, Elizabeth N., Mahar, Ernestine A., Lee, Michelle Y.H., Cohen, Joyce, Jean, Sherrie M., Wood, Jennifer S., Connor-Stroud, Fawn, Stammen, Rachelle L., Delmas, Olivia M., Wang, Shelly, Cooney, Kimberly A., Sayegh, Michael N., Wang, Lanfang, Filev, Peter D., Weiskopf, Daniela, Silvestri, Guido, Waggoner, Jesse, Piantadosi, Anne, Kasturi, Sudhir P., Al-Shakhshir, Hilmi, Ribeiro, Susan P., Sekaly, Rafick P., Levit, Rebecca D., Estes, Jacob D., Vanderford, Thomas H., Schinazi, Raymond F., Bosinger, Steven E., Paiardini, Mirko·2021·Cell

DOI 10.1016/j.cell.2020.11.007PMC PMC7654323

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 severity. Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages, and tissues was not reduced with baricitinib. Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib-treated animals had a rapid and remarkably potent suppression of lung macrophage production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2020.11.007

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Data Analysis
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4_9 · Cited by 12,675
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,037
UMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826

Show all 62 references

Sorted by citations

The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,477
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L. L., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,840
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 618
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern, D. J., Ai, Z., Ainsworth, M., Allan, C., Allcock, A., Angus, B., Ansari, M. A., Arancibia-Cárcamo, C. V., Aschenbrenner, D., Attar, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.012 · Cited by 328
The development of COVID-19 treatment
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125246 · Cited by 271
SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation
Thorne, L., Reuschl, A., Zuliani‐Alvarez, L., Whelan, M. V. X., Turner, J. L. E., Noursadeghi, M., Jolly, C. L., & Towers, G. J. (2021) · The EMBO Journal · doi:10.15252/embj.2021107826 · Cited by 223
Therapeutic potential of pyrrole and pyrrolidine analogs: an update
Basha, N. J., Basavarajaiah, S. M., & Shyamsunder, K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10387-8 · Cited by 205
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
Ely, E. W., Ramanan, A. V., Kartman, C. E., de Bono, S., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Saraiva, J. F. K., Chakladar, S., Marconi, V. C., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00006-6 · Cited by 194
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones
Collora, J. A., Liu, R., Pinto-Santini, D., Ravindra, N. G., Ganoza, C., Lama, J. R., Alfaro, R., Chiarella, J., Spudich, S., Mounzer, K., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.004 · Cited by 164
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Bonelli, M. M., Kerschbaumer, A., Kastrati, K., Ghoreschi, K., Gadina, M., Heinz, L. X., Smolen, J. S., Aletaha, D., O’Shea, J. J., & Laurence, A. D. J. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-223850 · Cited by 185
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!
Coperchini, F., Chiovato, L., & Rotondi, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668507 · Cited by 116
Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC)
Mohandas, S., Jagannathan, P., Henrich, T. J., Sherif, Z. A., Bime, C., Quinlan, E. B., Portman, M. A., Gennaro, M. L., Rehman, J., & RECOVER Mechanistic Pathways Task Force (2023) · eLife · doi:10.7554/elife.86014 · Cited by 120
Nonresolving inflammation redux
Nathan, C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.016 · Cited by 103
A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs
Routhu, N. K., Cheedarla, N., Gangadhara, S., Bollimpelli, V. S., Boddapati, A. K., Shiferaw, A., Rahman, S. A., Sahoo, A., Edara, V. V., Lai, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.001 · Cited by 85
Self-citation
JAK inhibitors: Ten years after
Spinelli, F. R., Meylan, F., O’Shea, J. J., & Gadina, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202048922 · Cited by 91
Haemophagocytic syndrome and COVID-19
Retamozo, S., Brito‐Zerón, P., Sisó‐Almirall, A., Flores-Chávez, A., Cárdenas, M. J. S., & Ramos‐Casals, M. (2021) · Clinical Rheumatology · doi:10.1007/s10067-020-05569-4 · Cited by 88
COVID-19 drug discovery and treatment options
Chan, J. F., Yuan, S., Chu, H., Sridhar, S., & Yuen, K. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01036-y · Cited by 92
Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
Hazeldine, J., & Lord, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680134 · Cited by 86
A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
Pino, M., Abid, T., Ribeiro, S. P., Edara, V. V., Floyd, K. A., Smith, J. C., Latif, M. B., Sánchez, G. P., Dutta, D., Wang, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abh3634 · Cited by 77
Self-citation
Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency
Magg, T., Okano, T., König, L. M., Boehmer, D. F. R., Schwartz, S. L., Inoue, K., Heimall, J. R., Licciardi, F., Ley‐Zaporozhan, J., Ferdman, R. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf9564 · Cited by 75
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy
Pillaiyar, T., & Laufer, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00335 · Cited by 70
JAK inhibitors and COVID-19
Levy, G., Guglielmelli, P., Langmuir, P. B., & Constantinescu, S. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002838 · Cited by 70
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Assadiasl, S., Fatahi, Y., Mosharmovahed, B., Mohebbi, B., & Nicknam, M. H. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1874 · Cited by 66
Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions
Han, Y., Yuan, K., Wang, Z., Liu, W., Lu, Z.-A., Liu, L., Shi, L., Yan, W., Yuan, J., Li, J., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01629-8 · Cited by 67
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
Perez‐Zsolt, D., Muñoz‐Basagoiti, J., Rodon, J., Elosua-Bayés, M., Regué, D. R., Risco, C., Sachse, M., Pino, M., Gumber, S., Paiardini, M., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00794-6 · Cited by 72
Self-citation
JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions
Beckman, J. D., DaSilva, A., Aronovich, E. L., Nguyen, A., Nguyen, J., Hargis, G. R., Reynolds, D. J., Vercellotti, G. M., Betts, B. C., & Wood, D. K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.01.027 · Cited by 67
Host cell-intrinsic innate immune recognition of SARS-CoV-2
Madden, E. A., & Diamond, M. S. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.002 · Cited by 60
SARS-CoV-2 Infection and Lung Regeneration
Zhao, F., Ma, Q., Yue, Q., & Chen, H. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00188-21 · Cited by 58
NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
Gillot, C., Favresse, J., Mullier, F., Lecompte, T., Dogné, J., & Douxfils, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.708302 · Cited by 57
Infiltration of inflammatory macrophages and neutrophils and widespread pyroptosis in lung drive influenza lethality in nonhuman primates
Corry, J., Kettenburg, G., Upadhyay, A. A., Wallace, M., Martí, M. M., Wonderlich, E. R., Bissel, S. J., Goss, K. L., Sturgeon, T. J., Watkins, S. C., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010395 · Cited by 56
Self-citation
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
Saber-Ayad, M. M., Hammoudeh, S. M., Abu‐Gharbieh, E., Hamoudi, R., Tarazi, H., Al‐Tel, T. H., & Hamid, Q. A. (2021) · Pharmaceuticals · doi:10.3390/ph14070680 · Cited by 55
Targeting the JAK2-STAT3 pathway to inhibit cGAS-STING activation improves neuronal senescence after ischemic stroke
Zhang, W., Xu, M., Chen, F., Su, Y., Yu, M., Xing, L., Chang, Y. E., & Yan, T. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114474 · Cited by 54
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling
Gajjela, B. K., & Zhou, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.016 · Cited by 50
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
Naik, R. R., Shakya, A. K., Aladwan, S., & El‐Tanani, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806568 · Cited by 50
Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection
Upadhya, S. W., Rehman, J., Malik, A. B., & Chen, S. (2021) · Physiology · doi:10.1152/physiol.00033.2021 · Cited by 54
Nanotechnology reinforced neutrophil-based therapeutic strategies for inflammatory diseases therapy
Wu, J., Ma, T., Zhu, M., Huang, T., Zhang, B., Gao, J.-Q., & Lin, N. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101577 · Cited by 48
STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer
Li, X., Jiang, W., Dong, S., Li, W.-C., Zhu, W., & Zhou, W. (2022) · Biomolecules · doi:10.3390/biom12101450 · Cited by 41
SARS-CoV-2 in animals: From potential hosts to animal models
Michelitsch, A., Wernike, K., Ulrich, L., Mettenleiter, T. C., & Beer, M. (2021) · Advances in virus research · doi:10.1016/bs.aivir.2021.03.004 · Cited by 47
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Sharun, K., Tiwari, R., Yatoo, M. I., Natesan, S., Megawati, D., Singh, K. P., Michalak, I., & Dhama, K. (2022) · Narra J · doi:10.52225/narra.v2i3.92 · Cited by 42
Involvement of Matrix Metalloproteinases in COVID-19: Molecular Targets, Mechanisms, and Insights for Therapeutic Interventions
Salomão, R., Assis, V., Neto, I. V. D. S., Petriz, B. A., Babault, N., Durigan, J. L. Q., & Marqueti, R. D. C. (2023) · Biology · doi:10.3390/biology12060843 · Cited by 44
RETRACTED ARTICLE: COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review
Attia, Y. A., El‐Saadony, M. T., Swelum, A. A., Qattan, S. Y. A., Al‐Qurashi, A. D., Asiry, K. A., Shafi, M. E., Elbestawy, A. R., Gado, A. R., Khafaga, A. F., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-13018-1 · Cited by 45
Retracted
Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway
Gu, S., Liang, J., Zhang, J., Liu, Z., Miao, Y., Wei, Y., Li, S., Gu, J., Cui, Y., Xiao, T., et al. (2023) · Molecules · doi:10.3390/molecules28052195 · Cited by 41
Targeting SARS-CoV-2 Non-Structural Proteins
Tam, W. G., Lorenzo‐Leal, A. C., Hernández, L. R., & Bach, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613002 · Cited by 39
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Treatments for COVID-19: Lessons from 2020 and new therapeutic options
Salasc, F., Lahlali, T., Laurent, E., Rosa‐Calatrava, M., & Pizzorno, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.002 · Cited by 39
SARS-CoV-2 immunity in animal models
Chen, Z., Yuan, Y., Hu, Q., Zhu, A., Chen, F., Li, S., Guan, X., Lv, C., Tang, T., He, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01122-w · Cited by 39
Transcriptional reprogramming of infiltrating neutrophils drives lung pathology in severe COVID-19 despite low viral load
Eddins, D. J., Yang, J., Kosters, A., Giacalone, V. D., Pechuan-Jorge, X., Chandler, J. D., Eum, J., Babcock, B. R., Dobosh, B. S., Hernandez, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008834 · Cited by 36
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
Solimani, F., Meier, K., & Ghoreschi, K. (2021) · European Journal of Immunology · doi:10.1002/eji.202149173 · Cited by 35
TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques
Upadhyay, A. A., Viox, E. G., Hoang, T. N., Boddapati, A. K., Pino, M., Lee, M. Y.-H., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37425-9 · Cited by 38
Self-citation
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
Richardson, P. J., Smith, D. P., de Giorgio, A., Snetkov, X., Almond-Thynne, J., Cronin, S., Mead, R. J., McDermott, C. J., & Shaw, P. J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00380-y · Cited by 35
SARS-CoV-2 Achieves Immune Escape by Destroying Mitochondrial Quality: Comprehensive Analysis of the Cellular Landscapes of Lung and Blood Specimens From Patients With COVID-19
Duan, C., Ma, R., Zeng, X., Chen, B., Hou, D., Liu, R., Li, X., Liu, L., Li, T., & Huang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946731 · Cited by 36
Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence
Strongin, Z., Marchand, L. R., Deléage, C., Pampena, M. B., Cardenas, M. A., Beusch, C. M., Hoang, T. N., Urban, E., Gourvès, M., Nguyen, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01875-0 · Cited by 37
Self-citation
Future applications of host direct therapies for infectious disease treatment
Thom, R. E., & D’Elia, R. V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436557 · Cited by 32
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis
Zhang, X., Shang, L.-H., Fan, G., Gu, X.-Y., Xu, J.-Y., Wang, Y.-M., Huang, L.-X., & Cao, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.800492 · Cited by 28
Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases
Xin, X., Wang, Y., Zhang, L., Zhang, D., Sha, L., Zhu, Z., Huang, X., Mao, W., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115102 · Cited by 34
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques
Viox, E. G., Hoang, T. N., Upadhyay, A. A., Nchioua, R., Hirschenberger, M., Strongin, Z., Tharp, G. K., Pino, M., Nguyen, K., Harper, J. L., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg0033 · Cited by 33
Self-citation
COVID-19 and Pregnancy: Vertical Transmission and Inflammation Impact on Newborns
Joma, M., Fovet, C.-M., Seddiki, N., Gressèns, P., & Laforge, M. (2021) · Vaccines · doi:10.3390/vaccines9040391 · Cited by 32
Immune-Guided Therapy of COVID-19
Ferraccioli, G., Gremese, E., Goletti, D., Petrone, L., Cantini, F., Ugel, S., Canè, S., & Bronte, V. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0675 · Cited by 30
Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors
Wu, A., Shi, K., Wang, J., Zhang, R., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115923 · Cited by 31
Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate
Patel, D., Field, C., Septer, K. M., Sim, D., Jones, M. J., Heinly, T., Vanderford, T., McGraw, E., & Sutton, T. (2021) · Journal of Virology · doi:10.1128/jvi.02232-20 · Cited by 26
Self-citation
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
Hasselbalch, H. C., Skov, V., Kjær, L., Ellervik, C., Poulsen, A., Poulsen, T. D., & Nielsen, C. H. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.03.006 · Cited by 30
Network analytics for drug repurposing in COVID-19
Siminea, N., Popescu, V., Martín, J. Á. S., Florea, D., Gavril, G., Gheorghe, A.-M., Iţcuş, C., Kanhaiya, K., Pacioglu, O., Popa, L. I., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab490 · Cited by 30
Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
Mooij, P., García‐Arriaza, J., Pérez, P., Lázaro-Frías, A., Verstrepen, B. E., Böszörményi, K. P., Mortier, D., Fagrouch, Z. C., Kiemenyi-Kayere, G., Niphuis, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845887 · Cited by 29
Luteolin inhibits spike protein of severe acute respiratory syndrome coronavirus‐2 ( SARS‐CoV ‐2) binding to angiotensin‐converting enzyme 2
Zhu, J., Yan, H., Shi, M., Zhang, M., Lu, J., Wang, J., Lu, C., Wang, Y., Li, L., Miao, L., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7826 · Cited by 31
COVID-19 Research: Lessons from Non-Human Primate Models
Albrecht, L., Bishop, E., Jay, B., Lafoux, B., Minoves, M., & Passaes, C. (2021) · Vaccines · doi:10.3390/vaccines9080886 · Cited by 30
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics
Kumar, S., Çalışkan, D. M., Janowski, J., Faist, A., Conrad, B. C. G., Lange, J., Ludwig, S., & Brunotte, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752227 · Cited by 28
Qingjin Huatan decoction protects mice against influenza a virus pneumonia via the chemokine signaling pathways
Liu, M., Zhao, F., Xu, J., Zhu, X., Zhao, Y., Wen, R., Anirudhan, V., Rong, L., Tian, J., & Cui, Q. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116745 · Cited by 28
Recent progress and prospects for anti-cytokine therapy in preclinical and clinical acute lung injury
Fadanni, G. P., & Calixto, J. Β. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.07.002 · Cited by 27
Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases
Hajjo, R., Sabbah, D. A., Abusara, O. H., Kharmah, R., & Bardaweel, S. K. (2023) · Viruses · doi:10.3390/v15020568 · Cited by 28
Progress and pitfalls of a year of drug repurposing screens against COVID-19
Sourimant, J., Aggarwal, M., & Plemper, R. K. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.06.004 · Cited by 26
Overview of Nonhuman Primate Models of SARS-CoV-2 Infection
Trichel, A. M. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-20-000119 · Cited by 28
Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators
Reece, M. D., Taylor, R. R., Song, C., & Gavegnano, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768695 · Cited by 26
COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
Khaledi, M., Sameni, F., Yahyazade, S., Radandish, M., Owlia, P., Bagheri, N., Afkhami, H., Mahjoor, M., Esmaelpour, Z., Kohansal, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961027 · Cited by 25
Neutrophil extracellular traps and neutrophilic dermatosis: an update review
Li, S., Ying, S., Wang, Y., Lv, Y., Qiao, J., & Fang, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01787-2 · Cited by 27
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Favalli, E. G., Maioli, G., & Caporali, R. F. (2024) · Drugs · doi:10.1007/s40265-024-02059-8 · Cited by 24
SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models
Kanimozhi, G., Bharathiraja, P., Pawar, C. S., Khan, H. A., Alrokayan, S., & Prasad, N. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638334 · Cited by 24
Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients
Wang, H., Zhang, J., Lu, Z., Dai, W., Ma, C., Xiang, Y., & Zhang, Y. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab373 · Cited by 23
Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis
Musiu, C., Caligola, S., Fiore, A., Lamolinara, A., Frusteri, C., Pizzo, F. D. D., Sanctis, F. D., Canè, S., Adamo, A., Hofer, F., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00866-0 · Cited by 23
Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID‐19
Yamamoto, Y., Shiroyama, T., Hirata, H., Kuge, T., Matsumoto, K., Yoneda, M., Yamamoto, M., Uchiyama, A., Takeda, Y., & Kumanogoh, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27421 · Cited by 24
Immune interventions in COVID-19: a matter of time?
Plaçais, L., Richier, Q., Noël, N., Lacombe, K., Mariette, X., & Hermine, O. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00464-w · Cited by 22
Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates
Stammes, M., Lee, J., Meijer, L., Naninck, T., Doyle-Meyers, L., White, A. G., Borish, H., Hartman, A., Alvarez, X., Ganatra, S. R., et al. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.12.001 · Cited by 20
Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update
Zhang, W., Qin, C., Fei, Y., Shen, M. Y., Zhou, Y., Zhang, Y., Zeng, X., & Zhang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109022 · Cited by 23
Differences in Vaginal Microbiota, Host Transcriptome, and Proteins in Women With Bacterial Vaginosis Are Associated With Metronidazole Treatment Response
Serebrenik, J., Wang, T., Hunte, R., Srinivasan, S., McWalters, J., Tharp, G. K., Bosinger, S. E., Fiedler, T. L., Atrio, J., Murphy, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab266 · Cited by 21
Self-citation
Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19
Wong, A. K. H., Woodhouse, I. B., Schneider, F., Kulpa, D. A., Silvestri, G., & Maier, C. L. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100321 · Cited by 26
Self-citation
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics
Chatterjee, B., & Thakur, S. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830990 · Cited by 23
ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis
Xiang, Y., Dai, J., Li, Y., You, Z., Zhang, J., Huang, X., Nie, S., Chen, Y., Xu, L., Liu, F., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00805-0 · Cited by 23
Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomised, Placebo-Controlled TrialPreprint
Ely, E. W., Ramanan, A. V., Kartman, C. E., de Bono, S., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Saraiva, J. F. K., Chakladar, S., & Marconi, V. C. (2021) · medRxiv · doi:10.1101/2021.10.11.21263897 · Cited by 22
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)
Martínez-Gualda, B., Schols, D., & Jonghe, S. D. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1928637 · Cited by 21
The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy
Wang, Y., Wu, M., Li, Y., Yuen, H. H., & He, M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00811-4 · Cited by 22
Development and Validation of a Stability-Indicating UV Spectroscopic Method for Baricitinib in Bulk and Formulation
Sri, K. B., Fatima, M. S., & Sumakanth, M. (2022) · Pharmaceutical Sciences and Drug Design · doi:10.51847/jxhxkcb6td · Cited by 20
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes
Dobosh, B., Zandi, K., Giraldo, D. M., Goh, S. L., Musall, K., Aldeco, M., LeCher, J., Giacalone, V. D., Yang, J., Eddins, D. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110945 · Cited by 19
Self-citation
Alveolar Macrophages in Viral Respiratory Infections: Sentinels and Saboteurs of Lung Defense
Pöpperl, P., Stoff, M., & Beineke, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010407 · Cited by 21
Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches
Choi, H., & Shin, E. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.1.152 · Cited by 19
Recent clinical findings on the role of kinase inhibitors in COVID-19 management
Malekinejad, Z., Baghbanzadeh, A., Nakhlband, A., Baradaran, B., Jafari, S., Bagheri, Y., Raei, F., Montazersaheb, S., & Farahzadi, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120809 · Cited by 20
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
Puhl, A. C., Gomes, G. F., Damasceno, S., Fritch, E. J., Levi, J. A., Johnson, N. J., Scholle, F., Premkumar, L., Hurst, B. L., Lee-Montiel, F., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02794 · Cited by 23
Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic
Jyonouchi, H. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1333717 · Cited by 20

Authors: Hoang, T. N., Pino, M., Boddapati, A. K., Viox, E. G., Starke, C. E., Upadhyay, A. A., Gumber, S., Nekorchuk, M., Busman-Sahay, K., Strongin, Z., Harper, J. L., Tharp, G. K., Pellegrini, K. L., Kirejczyk, S., Zandi, K., Tao, S., Horton, T. R., Beagle, E. N., Mahar, E. A., Lee, M. Y. H., Cohen, J., Jean, S. M., Wood, J. S., Connor-Stroud, F., Stammen, R. L., Delmas, O. M., Wang, S., Cooney, K. A., Sayegh, M. N., Wang, L., Filev, P. D., Weiskopf, D., Silvestri, G., Waggoner, J., Piantadosi, A., Kasturi, S. P., Al-Shakhshir, H., Ribeiro, S. P., Sekaly, R. P., Levit, R. D., Estes, J. D., Vanderford, T. H., Schinazi, R. F., Bosinger, S. E., & Paiardini, M.
Affiliations: Emory University (US)
Oregon Health & Science University (US)
La Jolla Institute for Immunology (US)
Case Western Reserve University (US)
Oregon National Primate Research Center (US)
Corresponding author: Schinazi, Raymond F.
Bosinger, Steven E.
Paiardini, Mirko
ORCID: Hoang, Timothy N.
Boddapati, Arun K.
Viox, Elise G.
Starke, Carly E.
Upadhyay, Amit A.
Gumber, Sanjeev
Harper, Justin L.
Tharp, Gregory K.
Pellegrini, Kathryn L.
Kirejczyk, Shannon
Zandi, Keivan
Mahar, Ernestine A.
Lee, Michelle Y.H.
Cohen, Joyce
Jean, Sherrie M.
Wood, Jennifer S.
Connor-Stroud, Fawn
Stammen, Rachelle L.
Wang, Shelly
Sayegh, Michael N.
Wang, Lanfang
Weiskopf, Daniela
Silvestri, Guido
Waggoner, Jesse
Piantadosi, Anne
Kasturi, Sudhir P.
Al-Shakhshir, Hilmi
Ribeiro, Susan P.
Levit, Rebecca D.
Estes, Jacob D.
Vanderford, Thomas H.
Schinazi, Raymond F.
Bosinger, Steven E.
Paiardini, Mirko
Venue: Cell
Publisher: Elsevier BV
Published: 2021-01
Volume: 184
Issue: 2
Pages: 460-475.e21
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2020.11.007
PMC: PMC7654323
OpenAlex: W3101403202
Cited by: 212
References: 62
Citations by year: 2026: 11 · 2025: 15 · 2024: 26 · 2023: 33 · 2022: 57 · 2021: 66
FWCI: 5.27
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 385 d)
Locations: Cell (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
PubMed Central (submittedVersion, cc-by-nc-nd)
Funders: Office of Research Infrastructure Programs, National Institutes of Health
National Institute of Allergy and Infectious Diseases
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Keywords: baricitinib, SARS-CoV-2, COVID-19 pandemic, JAK1/2 inhibitor, lung macrophages, neutrophil recruitment, NETosis, cytokine storm, lung inflammation, rhesus macaque model, viral shedding, type I interferon, SARS-CoV-2-specific T cells, cytokine and chemokine production

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks